{"id":9760,"date":"2004-05-02T19:10:36","date_gmt":"2004-05-02T19:10:36","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=9760"},"modified":"2014-05-22T17:25:10","modified_gmt":"2014-05-22T17:25:10","slug":"abacavir3tc-co-formulation-available-in-expanded-access","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/9760","title":{"rendered":"Abacavir\/3TC co-formulation available in expanded access"},"content":{"rendered":"<p><strong>The once-daily coformulation of abacavir\/3TC from GlaxoSmithKline is also progressing through the regulatory pipeline. Although expanded-access programmes are driven by medical urgency for a new compound prior to marketing approval, a programme is now available in the UK for patients who are in such a situation.<\/strong><\/p>\n<p>Doctors interested in accessing abacavir\/3TC in this formulation should contact Jan Williams (named-patient administrator) on 020 8990 2317 or GSK Medical Information on 0800 085 8747.<\/p>\n<p>Source: GSK expanded access programme<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The once-daily coformulation of abacavir\/3TC from GlaxoSmithKline is also progressing through the regulatory pipeline. Although expanded-access programmes are driven by medical urgency for a new compound prior to marketing approval, a programme is now available in the UK for patients &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-9760","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/9760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=9760"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/9760\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=9760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=9760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=9760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}